NovaBay Pharmaceuticals, Inc., a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, has recently been featured in a segment on San Francisco Bay area's KTVU-TV Channel 2 news and in an article in Genetic Engineering News.

The KTVU-TV segment highlights NovaBay's lead compound in development, NVC-422, as a new way of killing bacteria without developing resistance, which is a growing problem with currently available antibiotics. The interview with Dr. Ron Najafi provides a tour of NovaBay's lab facilities as well as an overview of the mechanism of action and therapeutic product opportunities for NVC-422. This novel product candidate is currently in human clinical trials for the treatment of a variety of infectious diseases. NVC-422 is based upon small molecules that white blood cells naturally produce to destroy microbes.

To continue reading this interesting article from Businesswire, click here.